IL10 and campylobacteriosis: In our present pre-clinical intervention trial, we tested the effects of oral AC versus placebo prophylaxis in the course of campylobacteriosis in hma IL-10−/− mice and found (i) comparable gastrointestinal pathogen burdens upon C. jejuni infection, but (ii) pronounced C. jejuni induced clinical signs such as wasting symptoms and bloody diarrhea in placebo as opposed to AC challenged mice, that were accompanied by (iii) less distinct apoptotic and (iv) pro-inflammatory immune responses in the colon of the latter versus the former.